RxDoctor Payments Data

Joshua Yuen, MD

Internal Medicine · Louisville, KYNPI 1235495375

Payments from drug & device makers

$724in general payments, 2019–2025

Across 23 payments — averaging $31.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$171
  • Phathom Pharmaceuticals, Inc.$125
  • Lilly USA, LLC$107
  • Biohaven Pharmaceuticals, Inc.$88
  • Johnson & Johnson$84
  • Novo Nordisk$27
  • plus $121 from 8 others

What the payments were for

  • Food & beverage$724100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$724 in reported general payments places this provider in the 55th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$54,235
Medicare patients
124
Services billed
872

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide96$102,929
EliquisApixaban64$68,168
JardianceEmpagliflozin32$31,946
MounjaroTirzepatide27$27,976
Stiolto RespimatTiotropium Br/Olodaterol Hcl37$23,420
JanuviaSitagliptin Phosphate15$16,212
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$3,605
Duloxetine Hcl124$2,353
Atorvastatin Calcium345$2,220
Pregabalin36$1,718
Metoprolol Succinate102$1,392
Levothyroxine Sodium152$1,329
Diclofenac Sodium45$1,327
Gabapentin101$1,279
Omeprazole145$1,151

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$27$102,92996 claims
PfizerEliquis$12$68,16864 claims
Lilly USA, LLCMounjaro$107$27,97627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →